Amicus Therapeutics Inc Analyst Day Transcript
Good morning, everyone. Welcome to our Amicus Analyst Day 2019. I'm Sara Pellegrino, Head of Investor Relations, and would like to welcome everybody here today.
We will be making forward-looking statements during this Analyst Day, so we'll reference Slide 2. For those of you who are listening remotely, the slides are available right now on the IR section of our website, if you want to follow along with the presentation.
We have a very full agenda this morning, and so we want to make sure that we move through in a timely manner so that we can cover all of the topics that we would like to get to. We'll be covering the vision, mission and strategy. We'll be providing a financial and operational strategy and outlook. We'll be covering Galafold and the road map to $1 billion in sales and include some patient perspectives there. We'll also cover AT-GAA, our crown jewel for Pompe disease as well as our next-generation research and Gene Therapy Program and a special feature on our Batten disease gene therapy
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |